The urokinase-type plasminogen activator receptor (uPAR) has been implicated as a modulator of several biochemical processes that are active during tumor invasion and metastasis, e.g. extracellular proteolysis, cell adhesion, and cell motility. The structural basis for the high affinity interaction between the urokinase-type plasminogen activator (uPA) and uPAR, which focuses cell surface-associated plasminogen activation in vivo, is now thoroughly characterized by site-directed mutagenesis studies and x-ray crystallography. In contrast, the structural basis for the interaction between uPAR and the extracellular matrix protein vitronectin, which is involved in the regulation of cell adhesion and motility, remains to be clarified. In this study, we have identified the functional epitope on uPAR that is responsible for its interaction with the full-length, extended form of vitronectin by using a comprehensive alanine-scanning library of purified single-site uPAR mutants (244 positions tested). Interestingly, the five residues identified as "hot spots" for vitronectin binding form a contiguous epitope consisting of two exposed loops connecting the central four- The urokinase-type plasminogen activator receptor (uPAR 2 / CD87) is a modular, glycolipid-anchored membrane protein (1, 2). Through the specific binding of the urokinase-type plasminogen activator (uPA), uPAR assists in regulating and focalizing cell surface-associated plasminogen activation as demonstrated both in vitro (3, 4) and in vivo (5-7). The high affinity interaction between uPAR and uPA (K D Ͻ 1 nM) has been extensively characterized (2, 8) . Although all determinants required for this tight binding are contained within the small growth factor-like domain of uPA (GFD residues 1-48) (9), it critically depends on maintenance of a three-domain, modular structure of uPAR (10). Accordingly, site-directed mutagenesis and photoaffinity labeling studies have shown that elements located in distinct domains of uPAR are involved in the interactions with both uPA (8, 11-13) and a potent 9-mer peptide antagonist (9, 14 -16). Two crystal structures solved for uPAR in complex with either a linear peptide antagonist (17) or the amino-terminal fragment (ATF) of uPA (18, 19) have provided the structural basis for the existence of a composite ligandbinding site. The assembly of the three homologous domains in uPAR creates a large and deep central ligand-binding cavity, where aliphatic side chains, provided by uPAR domain I, establish a hydrophobic binding site on one side of the cavity. The high affinity for both uPA and the linear peptide antagonists is achieved by an intimate interaction with this cavity (8, 17, 18) , providing a well defined target site for rational drug design (20) .
The urokinase-type plasminogen activator receptor (uPAR) has been implicated as a modulator of several biochemical processes that are active during tumor invasion and metastasis, e.g. extracellular proteolysis, cell adhesion, and cell motility. The structural basis for the high affinity interaction between the urokinase-type plasminogen activator (uPA) and uPAR, which focuses cell surface-associated plasminogen activation in vivo, is now thoroughly characterized by site-directed mutagenesis studies and x-ray crystallography. In contrast, the structural basis for the interaction between uPAR and the extracellular matrix protein vitronectin, which is involved in the regulation of cell adhesion and motility, remains to be clarified. In this study, we have identified the functional epitope on uPAR that is responsible for its interaction with the full-length, extended form of vitronectin by using a comprehensive alanine-scanning library of purified single-site uPAR mutants (244 positions tested). Interestingly, the five residues identified as "hot spots" for vitronectin binding form a contiguous epitope consisting of two exposed loops connecting the central fourstranded ␤-sheet in uPAR domain I (Trp 32 The urokinase-type plasminogen activator receptor (uPAR 2 / CD87) is a modular, glycolipid-anchored membrane protein (1, 2) . Through the specific binding of the urokinase-type plasminogen activator (uPA), uPAR assists in regulating and focalizing cell surface-associated plasminogen activation as demonstrated both in vitro (3, 4) and in vivo (5) (6) (7) . The high affinity interaction between uPAR and uPA (K D Ͻ 1 nM) has been extensively characterized (2, 8) . Although all determinants required for this tight binding are contained within the small growth factor-like domain of uPA (GFD residues 1-48) (9) , it critically depends on maintenance of a three-domain, modular structure of uPAR (10) . Accordingly, site-directed mutagenesis and photoaffinity labeling studies have shown that elements located in distinct domains of uPAR are involved in the interactions with both uPA (8, (11) (12) (13) ) and a potent 9-mer peptide antagonist (9, 14 -16) . Two crystal structures solved for uPAR in complex with either a linear peptide antagonist (17) or the amino-terminal fragment (ATF) of uPA (18, 19) have provided the structural basis for the existence of a composite ligandbinding site. The assembly of the three homologous domains in uPAR creates a large and deep central ligand-binding cavity, where aliphatic side chains, provided by uPAR domain I, establish a hydrophobic binding site on one side of the cavity. The high affinity for both uPA and the linear peptide antagonists is achieved by an intimate interaction with this cavity (8, 17, 18) , providing a well defined target site for rational drug design (20) .
As opposed to this, the binding sites mediating the interactions between uPAR and its auxiliary binding partners, e.g. vitronectin (21, 22) and integrins (23, 24) , must reside outside this cavity, but the molecular mechanisms underlying these interactions are largely unknown. As these interactions are dependent on or modulated by receptor occupancy with uPA (22, (25) (26) (27) , uPAR may orchestrate the assembly of these ternary complexes on the cell surface and thus assist in the regulation of cell adhesion and migration. In accordance with this proposition, it has been reported that cell lines with low endogenous uPAR expression adhere poorly to vitronectin, but this adhesion is markedly promoted by receptor saturation with exogenously added uPA (21, 27) . Increased uPAR expression in vitro by transfection or cytokine treatment may, however, uncouple this ligand dependence enabling adhesion to vitronectin by a local high density of unoccupied uPAR (27) . Partitioning into lipid rafts may generate such a local high density of uPAR and could thus play a regulatory role for uPARmediated vitronectin adhesion (28) .
In contrast to the well characterized uPAR-ATF interaction, the structural elements in the uPAR⅐uPA complex that are responsible for the interaction with matrix-deposited vitronec-tin are largely undefined. Two important functional relationships have nonetheless been established for this interaction. First, the binding sites for uPA and vitronectin on uPAR must be completely nonoverlapping because of the ability to form tri-molecular complexes. Second, the integrity of the intact three-domain structure of uPAR is mandatory for this complex formation (27, 29) . So far, only one study (12) has sought to define the functional epitope on uPAR for this interaction. Using homologue-scanning mutagenesis, by which segments of the individual domains of uPAR were swapped with the corresponding sequences in the single domain homologue CD59, Li et al. (12) 3 were important for vitronectin binding but not for uPA binding. To gain further insight into the molecular details of this interaction, we have therefore probed the interaction between purified prouPA⅐uPAR complexes and vitronectin by using an almost complete alanine-scanning library of single-site uPAR mutants. We find that the functional epitope for this interaction encompasses a small region located outside the central uPA-binding cavity and involves residues in two loops connecting the central four-stranded ␤-sheet in uPAR domain I as well as residues in the linker peptide connecting uPAR domains I and II. Intriguingly, this functional epitope on uPAR for vitronectin binding resembles the corresponding binding site on PAI-1 for the somatomedin B-like (SMB) domain of vitronectin as both interactions employ arginine as the critical hot spot residue. Protein Preparations-Monomeric human vitronectin purified from plasma was obtained from Molecular Innovations (Southfield, MI). Recombinant active PAI-1 produced in Escherichia coli was a kind gift from Dr. M. D. Andersen (NOVONordisk, Denmark). The monoclonal anti-uPAR antibody R2 (30) , which also recognizes uPAR-vitronectin complexes (29) , was produced in-house and was labeled with Eu 3ϩ using the stable Eu 3ϩ -chelate of
MATERIALS AND METHODS

Chemicals and Reagents-All
,N 3 ,N 3 -tetraacetic acid at pH 9.3 and a molar ratio of 20:1. This procedure yielded a labeling density of 2-4 molecules of Eu 3ϩ per R2. The monoclonal anti-uPA clone 5 as well as a mixture of four monoclonal anti-PAI-1 antibodies (clones 2, 3, 5, and 7) also prepared in-house were labeled with Eu 3ϩ following the same procedure. Expression and Purification of Soluble Recombinant Human uPAR-Soluble forms of human uPAR were expressed and secreted by Chinese hamster ovary cells (CHO) or Drosophila melanogaster Schneider 2 (S2) cells, which were stably transfected with either suPAR (residues 1-277) (33) or pMTC/uPAR (residues 1-283) (31) . These proteins are secreted to the conditioned medium because of a deletion of the carboxyl-terminal signal sequence that is required for glycolipid anchoring (1, 2) . Single-site alanine replacements were introduced into pMTC/ uPAR by site-directed mutagenesis using a previously designed three-gene cassette approach (31) , and the corresponding soluble uPAR mutants (244 in all) were expressed by S2 cells and immunoaffinity-purified as described (8) 82 . In addition, selected positions were mutated to residues other than alanine. The following mutants were produced: R30E, R30D, R30K, W32F, W32Y, E37K, R58K, R58E, R58D, I63L, I63V, R91D, R91E, R91K, Y92F, and Y92W. All constructs were verified by DNA sequencing using an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA), and the identities of the individually purified uPAR mutants were also verified at the protein level by peptide-mass mapping using in-gel digestion of the reduced and alkylated protein followed by mass assignment and MS/MS-sequencing using an Autoflex TM TOF-TOF II (8) . As judged from SDS-PAGE of ϳ5 g of reduced and alkylated sample, the purity of these uPAR mutant preparations was Ͼ95%. Concentrations of purified uPAR WT were accurately quantified by amino acid composition analyses (32) . Protein concentrations of the purified uPAR mutants were determined using an extinction coefficient E 280nm 1% of 9.2 (33) S356A and Human Vitronectin Fragments-Human prouPA was produced by Drosophila S2 cells stably transfected with a pMTB/uPA (residues 1-411) vector. Expression of prouPA WT or the active site-mutated pro-uPA S356A was induced by 0.5 mM Cu 2 SO 4 as described previously (31) , but in this particular case the S2 media also contained 10 g/ml aprotinin to prevent activation of pro-uPA. The pro-uPA was isolated by immunoaffinity chromatography using an immobilized antiuPA monoclonal antibody (clone 6). The purity of this pro-uPA was Ͼ95%, and the preparation showed no evidence of conversion as judged by SDS-PAGE. The identity of the purified prouPA was verified by MS as described (8) . Protein concentration of a stock solution of pro-uPA S356A was accurately determined by amino acid composition analysis (32) .
Vitronectin fragment 1-121 was expressed in S2 cells using the expression vector pMTC/Vn-(1-121)/uPAR-DIII (34) . This construction covers vitronectin residues 1-121 followed by an enterokinase cleavage sequence (DDDDK) and finally a carboxyl-terminal tag comprising uPAR domain III (uPAR-DIII residues 182-283) to assist subsequent immunoaffinity purification (34) . The following single-site alanine replacements (F13A, V15A, D22A, E23A, L24A, S26A, Y27A, Y28A, and Q29A) as well as the double substitutions (T50A/T57A and T50E/T57E) were introduced into pMTC/Vn-(1-121)/uPAR-DIII as described previously (35) . All constructs were verified by DNA sequencing. These fusion proteins were purified by immunoaffinity chromatography using an immobilized antiuPAR antibody (R2), as outlined previously for the purification of uPAR, and used as uncleaved fusion proteins.
Human GFD-(1-48) and SMB-(1-47) domains fused to a carboxyl-terminal His 6 tag were expressed by stably transfected Pichia pastoris strain X-33 using the yeast expression vector pPICZ␣. The secreted domains were purified by Ni 2ϩ -nitrilotriacetic acid affinity chromatography followed by reversedphase chromatography as described previously (8) .
Assessing S356A and 100 nM uPAR were preformed by incubation for 30 min at room temperature, and the interaction with immobilized vitronectin was subsequently allowed to proceed for 60 min at room temperature on an orbital shaker. All incubations and dilutions were performed in DELFIA assay buffer (50 mM Tris-buffered saline, pH 7.8, containing 0.5% (w/v) BSA, bovine immunoglobulin, 0.04% (v/v) Tween 40, and 20 M diethylenetriaminepentaacetic acid). After washing the fluoroplates six times, they were incubated for 60 min with 0.6 g/ml of the Eu 3ϩ -labeled R2 monoclonal anti-uPAR antibody in DELFIA assay buffer followed by six additional washes. Finally, the Eu 3ϩ attached to the receptorbound R2 was dissociated from its chelator by incubation in DELFIA enhancement solution for 5 min. The fluorescence of the free Eu 3ϩ was measured by time-resolved fluorescence using a Fluostar Galaxy fluorometer (PerkinElmer Life Sciences) with excitation set at 340 nm and reading emission at 615 nm with a 400-s delay and a 400-s acquisition window.
In a modified version of this binding assay, fusion proteins containing derivatives of vitronectin linked to uPAR domain III (Vn-(1-121)/uPAR-DIII) were immobilized on white Maxisorb fluoroplates using a 2-fold dilution series in coating buffer covering 0.12 to 1 g/ml. After blocking excess binding sites as described above, the coated wells were either incubated with preformed pro-uPA⅐uPAR complexes (100 nM uPAR preincubated with 10 nM pro-uPA S356A as described above), 10 nM active PAI-1, or with buffer alone. In these experiments the DELFIA assay buffer included an additional 0.1% (v/v) Tween 20 and 0.25 M NaCl. The level of immobilized fusion protein was assessed by adding 0.6 g/ml of the Eu 3ϩ -labeled monoclonal anti-uPAR antibody R2 to wells incubated with buffer only. Quantification of the pro-uPA-uPAR interaction with the immobilized vitronectin fusion proteins was accomplished by incubating the relevant wells with the Eu 3ϩ -labeled monoclonal anti-uPA antibody clone 5 and measuring the released Eu 3ϩ as described above. PAI-1 binding was measured by a similar approach after incubation with a Eu 3ϩ -labeled mixture of four monoclonal anti-PAI-1 antibodies.
Surface Plasmon Resonance Studies-All real time interaction studies were carried out on a Biacore 3000 TM instrument (Biacore, Uppsala, Sweden) using 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) surfactant P-20 at pH 7.4 as running buffer. Human recombinant pro-uPA S356A (0.25 to 1 g/ml) was immobilized covalently on a carboxymethylated dextran matrix (CM5 sensor chip) using N-hydroxysuccinimide/N-ethyl-NЈ- [3-(diethylamino) propyl]carbodiimide as described previously (11) . To obtain comparative evaluations of the kinetics for the uPA-uPAR interaction, 2-fold serial dilutions of the various uPAR mutants (2-200 nM in running buffer) were analyzed in parallel for uPA binding at a flow rate of 50 l/min at 20°C. Compared with previous studies (8, 11) , in this study we have used a very high flow rate to minimize effects from mass transport limitations on the assessment of the kinetic rate constants. After each run the sensor chip was regenerated by two consecutive injections of 0.1 M acetic acid in 0.5 M NaCl. The kinetic rate constants, k on and k off , were derived from these real time interaction analyses by fitting the association and dissociation phases to a bimolecular interaction model using the BIAevaluation 4.1 software (Biacore, Uppsala, Sweden), as described in detail previously (8) .
For direct affinity measurements of the SMB-uPAR interaction, purified human uPAR WT , uPAR W32A , and uPAR R91A (2.5 g/ml) were immobilized by conventional amine chemistry in separate flow cells on a single CM5 sensor chip with coupling yields ranging from 1,500 to 2,000 RU. 
The equilibrium binding (R eq ) and binding capacity (R max ) of the sensor chip are determined in resonance units (RU), but these can be transformed into binding densities using the approximation that 1000 RU equals 1 ng/mm 2 . For affinity measurements of the interaction between SMB and preformed pro-uPA⅐uPAR complexes, the immobilized uPAR mutants were initially saturated by 200-l injections of 200 nM solutions of pro-uPA S356A , ATF-(1-143), or GFD-(1-48) before 67 l of 2-fold serial dilution series of SMB were injected (up to 10 M).
RESULTS
Quantification of the Interaction between Immobilized
Vitronectin and Pro-uPA⅐uPAR Complexes Using Time-resolved Fluorescence-Cellular attachment and adhesion studies to vitronectin are often conducted with immobilized protein in microtiter plates because the adsorbed vitronectin in such studies is considered a suitable in vitro surrogate for the natural, matrix-embedded protein. Several experiments employing either cell cultures (21, 27) or purified components (25, 29) clearly demonstrate that the interaction between uPAR and vitronectin is largely dependent on the degree of saturation of uPAR with uPA. In this study we have used a time-resolved immunofluorescence assay in microtiter plates to facilitate the accurate quantification of uPAR-vitronectin complexes. This method detects binding of preformed pro-uPA⅐uPAR complexes to immobilized vitronectin using a high affinity monoclonal anti-uPAR antibody (R2), which is conjugated with chelated Eu 3ϩ as a time-resolved fluorescence reporter. In this experimental setting, unoccupied uPAR shows virtually no interaction with immobilized vitronectin at concentrations of up to 800 nM ( Fig. 1, upper panel) . In contrast, formation of pro-uPA⅐uPAR complexes by addition of the active site-mutated pro-uPA S356A results in a high affinity interaction between these soluble complexes and immobilized vitronectin. Saturation occurs roughly at equimolarity, as shown for the titration of various fixed concentrations of pro-uPA with uPAR ( Fig. 1 , upper panel) and vice versa (Fig. 1, lower panel) . Studies conducted in parallel with pro-uPA WT rather than the active site mutant yielded comparable binding isotherms (data not shown). The presence of a molar excess of pro-uPA relative to uPAR has an inhibitory impact on the pro-uPA-uPARvitronectin interaction, which is evident from both dose-response profiles outlined in Fig. 1 . Nevertheless, using the correct conditions this assay is ideally suited to the large scale screening of uPAR mutants for vitronectin binding. If, as illustrated by the dose-response profiles for the pro-uPA-uPARvitronectin interactions (Fig. 1, upper panel) , a molar excess of uPAR (100 nM) is analyzed in the presence of limiting amounts of pro-uPA (10 nM), the method becomes relatively insensitive to variations in the concentration of the tested uPAR. Next, the use of high concentrations of both uPAR and pro-uPA relative to the K D for their binding will minimize the impact of uPAR mutations that moderately affects uPA binding rather than having a direct effect on vitronectin binding. Under these conditions the amount of preformed uPA⅐-uPAR complexes is thus primarily controlled by the concentration of pro-uPA, which is kept constant.
Mapping the Functional Epitope on uPAR for Vitronectin Binding by Alanine-scanning Mutagenesis-To probe the relative contribution of the individual amino acid side chains in uPAR to the vitronectin binding properties of the corresponding pro-uPA⅐uPAR complexes, we have individually substituted 244 of the 283 residues in a truncated, soluble uPAR with alanine. Residues defining the consensus sequence of the Ly6/ uPAR/␣-neurotoxin protein domain family (2, 36) were excluded on structural grounds. In cases where the authentic uPAR residue is an alanine, it was replaced by serine, and the five asparagine residues accounting for all the possible N-linked glycosylation-sites were replaced individually by glutamine. The interactions of preformed pro-uPA⅐uPAR complexes (10 nM) with immobilized vitronectin were measured for all individual uPAR mutants relative to uPAR WT (Figs. 2-4 ). Evaluation of this complete alanine-scanning mutagenesis of uPAR reveals that the functional epitope for vitronectin binding of pro-uPA⅐uPAR complexes consists of three hot spot residues in uPAR domain I, Trp 32 , Arg 58 , and Ile 63 (Fig. 2) ; two hot spots in the linker region between domains I and II, Arg 91 and Tyr 92 (Fig. 3) ; and two charged residues of moderate importance in uPAR domain I, Arg 30 and Glu 37 (Fig. 2) . None of these seven residues are involved in the high affinity interaction with uPA, because their alanine mutants did not have a significant effect on the kinetic rate constants for this interaction as assessed by surface plasmon resonance (Table 1 ) (8) . In a parallel experiment, the alanine mutants of uPAR were tested for vitronectin binding in the presence of a higher concentration of pro-uPA (25 nM), and an identical profile for the pro-uPA-uPARvitronectin interaction was observed demonstrating that for-FIGURE 1. Dose-response of the interaction between pro-uPA⅐uPAR complexes and immobilized vitronectin. In the upper panel different concentrations of pro-uPA S356A were allowed to equilibrate for 30 min with serial dilutions of uPAR WT (produced in CHO cells) before the preformed pro-uPA⅐uPAR complexes were transferred to vitronectin-coated wells, and binding proceeded for 60 min at room temperature. The bound uPAR was subsequently reacted with a Eu 3ϩ -labeled monoclonal anti-uPAR antibody (R2) and finally quantified by time-resolved fluorescence of the dissociated Eu 3ϩ . The following pro-uPA concentrations were tested: 0 nM (छ), 5 nM (OE), 10 nM (‚), 20 nM (F), and 40 nM (E). The inset shows the linear dose-response curve for the vitronectin interaction in the presence of 100 nM uPAR. In the lower panel the inverse experiment has been performed in which fixed concentrations of uPAR WT (10 nM (ƒ), 20 nM (f), and 40 nM (Ⅺ)) were allowed to equilibrate with serial dilutions of pro-uPA S356A before reaction with immobilized vitronectin. The inset shows the uPA dependence for the binding of 40 nM uPAR to immobilized vitronectin. Raw fluorescence data are shown in both cases, but generally the nonspecific signal from noncoated wells treated in parallel never exceeded 10%. Arrows indicate the concentration of uPAR (upper panel) or pro-uPA (lower panel) causing saturation of the vitronectin binding, which occurs at a roughly 1:1 stoichiometry in both cases. Each data point represents the mean of two replicate measurements. The concentrations of the proteins used in these experiments were carefully determined by amino acid analysis.
mation of pro-uPA⅐uPAR complexes is not a limiting factor (data not shown).
A few residues were found to affect vitronectin binding upon alanine replacement but were not considered part of the functional epitope. The effect observed with alanine substitution of The error bars for the individual mutants represent the standard deviation for data derived from 4 to 10 separate determinations measured relative to a uPAR WT standard analyzed in parallel on all plates. Binding of uPAR to vitronectin was quantified by the Eu 3ϩ fluorescence released from bound Eu 3ϩ -labeled R2 as specified in Fig. 1 , but in this case the fluorescence from noncoated wells treated in parallel has been subtracted. Arbitrary cut-off levels for vitronectin reactivity of these mutants are set at 25 Defining the functional epitope in uPAR domain II for the interaction between pro-uPA⅐uPAR complexes and immobilized vitronectin by alanine-scanning mutagenesis. These data were generated as outlined in Fig. 2 113 and Glu 120 is most likely caused by structural perturbations as these residues have a limited surface exposure in the x-ray structure of uPAR, and furthermore uPAR L113A is the only mutation found that seriously affects vitronectin as well as uPA binding.
Leu 113 (Fig. 3 ) is most likely caused by structural perturbation as this residue has a limited surface exposure in the x-ray structures of uPAR (17, 18) . Furthermore, Leu 113 is the only alanine mutation found to seriously affect vitronectin as well as uPA binding (8) . These considerations also apply to the moderate impact of mutation of Glu 120 (Fig. 3) as this residue is known to be involved in the interdomain interaction between uPAR domains I and II (17, 18) . Finally, the pronounced effect observed upon mutation of Asp 275 (Fig. 4) is not related to impaired vitronectin binding but to impaired detection by the Eu 3ϩ -labeled R2 as this residue is the key hot spot of the functional epitope for this monoclonal antibody (data not shown) (34) .
Alanine substitution of residues that were previously assigned to the functional epitope for uPA binding (e. R91A , but the actual charge contribution from this hot spot residue cannot be established in this experiment because the alanine mutation of Arg 91 on its own reduces the interaction with immobilized vitronectin to a level that is very close to the base-line reaction observed in the absence of uPAR (Fig. 5) . None of the differential mutations replacing the surface-exposed Arg 91 have any significant impact on uPA binding (Table 1) , which is concordant with its location outside the central uPA-binding cavity (17, 18) .
We next addressed the importance of the aromatic side chains of Trp 32 and Tyr 92 . Substitutions of Trp 32 with other aromatic side chains only marginally improved the vitronectin binding compared with the alanine mutant, and binding was still far below that of uPAR WT (Fig. 5) highlighting the importance of the indole side chain at this position. By contrast, the impaired vitronectin binding of uPAR Y92A was almost completely restored to wild-type levels in uPAR Y92F and uPAR Y92W . This observation argues for a role of the planar aromatic side chain rather than the involvement of specific hydrogen bonding of the hydroxyl group of Tyr 92 . None of the mutations of aromatic side chains have any measurable effect on uPA binding (Table 1) . is not a consequence of an impaired reactivity with immobilized vitronectin but is caused by its impaired reactivity with the Eu 3ϩ -labeled R2 monoclonal anti-uPAR antibody used for detection.
Finally, conservative replacements of Ile 63 with Leu or Val revealed differing effects on vitronectin binding with the clear preference of Ile Ͼ Val Ͼ Ͼ Leu and Ala for optimal binding (Fig.  5) . This demonstrates the limited spatial freedom in the geometry of the C ␥ and C ␦ atoms that is allowed at this position. A previous study (12) reported that residues 172-175 and 183-186 of uPAR are involved in the interaction with vitronectin based on homology-scanning mutagenesis, where short, selected peptide sequences in uPAR were exchanged individually with the corresponding sequences in CD59, a single domain member of the Ly6/uPAR/␣-neurotoxin protein domain family (2, 36) . However, our present alanine-scanning mutagenesis of uPAR does not implicate any single residue in these two regions as being of importance for the interaction with vitronectin, when mutated individually to alanine (Figs. 3 and 4) . We therefore constructed the two relevant uPAR mutants (uPAR N172-K175/CD59 and uPAR E183-N186/CD59 ) and measured the kinetic rate constants for their interaction with uPA by surface plasmon resonance as well as their capacity for vitronectin binding in the time-resolved fluorescence assay. Both of these tetra-mutants exhibited unaltered uPA binding (Table 1 ), but we found that they also retained close to normal vitronectin binding (Fig. 5) in accordance with the data obtained in the single-site alanine-scanning mutagenesis.
SMB Exploits the Same Hot Spot as Vitronectin for Its Low
Affinity Binding to uPAR-As the engagement of vitronectin in uPAR and PAI-1 binding is largely governed by the small amino-terminal SMB domain (37, 38), we next investigated this interaction by surface plasmon resonance using comparable levels of immobilized uPAR WT , uPAR W32A , and uPAR R91A . Initially, the binding capacity (B max ) and kinetic rate constants for the high affinity interaction with purified GFD were established for each flow cell containing one of these uPAR mutants (Fig. 6 , upper panel, and Table 2 ). The corresponding kinetic rate constants for the interaction between immobilized uPAR WT and SMB were too fast, however, to be quantified reliably by the Biacore3000 TM (Fig. 6, middle panel) . This particular interaction was consequently analyzed under conditions yielding equilibrium binding. As illustrated in Fig. 6 (lower panel) , this revealed a specific interaction between uPAR WT and SMB, whereas the linear and parallel dose-response profiles recorded for uPAR W32A and uPAR R91A are indicative of nonspecific binding (solid lines). Taking further advantage of this observation, we used the dose-response profile recorded for uPAR R91A as an approximation for the subtraction of nonspecific binding to uPAR WT . The resultant binding isotherm for the SMBuPAR WT interaction was subsequently fitted to saturation of a single binding site (Fig. 6, lower panel, broken line) . This yields a K D of 1.9 M for the SMB-uPAR WT interaction and a binding capacity for the chip of 8.5 fmol of SMB/mm 2 ( Table 2) . Reassuringly, the SMB and GFD modules bind with a similar stoichiometry to the immobilized uPAR WT (i.e. comparable binding capacities) despite their widely differing K D -values (Table  2) . These data clearly demonstrate that SMB exploits the same hot spot binding site on uPAR as intact immobilized vitronectin. Unfortunately, a similar quantitative interaction analysis using intact vitronectin is precluded because of the instability and heterogeneous state of this purified protein preparation.
Our solid phase fluorescence assay used to screen the uPAR mutant library for vitronectin binding clearly reveals the dependence of this interaction on pro-uPA complex formation (Fig. 1A) . We therefore modified the surface plasmon resonance experiment described above to allow saturation of immobilized uPAR with GFD, ATF, or pro-uPA before recording the dose-response profiles between these preformed complexes and a 2-fold serial dilution series of SMB (Fig. 7A) . No significant binding of SMB was observed for any complexes containing uPAR W32A or uPAR R91A (data not shown). Evaluation of the equilibrium binding constants for the SMB interaction with unoccupied uPAR WT and preformed uPAR WT complexes with GFD, ATF, or pro-uPA reveals some interesting differences ( Fig. 7B and Table 3 ). First, the equilibrium dissociation constant (K D ) for the SMB interaction is decreased 4-fold upon occupation of the large hydrophobic binding cavity with receptor binding derivatives of uPA (Table 3) . Second, this tighter binding is accompanied by an ϳ30% increase in the apparent binding capacity of the chip for SMB, which indicates that "latent" uPAR molecules are rendered SMB-binding competent by the occupation of the central uPA-binding cavity.
Comparison of the Functional Epitopes in SMB for ProuPA⅐uPAR Complexes and for PAI-1-
We finally probed the importance of selected positions within the PAI-1 binding region of vitronectin (i.e. the SMB domain) for the interaction with preformed pro-uPA⅐uPAR complexes. To this end we expressed a fusion protein encompassing the first 121 residues of vitronectin linked to uPAR domain III (Vn-(1-121) uPAR-DIII) in Drosophila S2 cells (34) . Comparable levels of the purified constructs with single-site mutations in the SMB domain were immobilized on microtiter plates as determined by detection with Eu 3ϩ -labeled R2. We found that this construct retained the capability of full-length vitronectin to bind preformed pro-uPA⅐uPAR complexes (Fig. 8) as well as PAI-1 (data not shown). This partial alanine-scanning analysis identified five positions in SMB that are important for the interaction with preformed uPAR⅐pro-uPA complexes as follows: Phe 13 , Asp 22 , Leu 24 , Tyr 27 , and Tyr 28 . Two threonine residues located outside this domain (Thr 51 and Thr 57 ), which have been reported to be phosphorylated (39), do not play a significant role in either of these interactions.
The present alanine-scanning mutagenesis of SMB largely confirms data obtained from a previous mutagenesis study (38) , with the exceptions that we did not identify Glu 23 as a functionally important residue for binding uPAR⅐pro-uPA complexes, but we did find Phe 13 to be important.
DISCUSSION
In this study we have characterized the complete functional epitope on the uPAR that is responsible for the binding of uPA⅐ uPAR complexes to immobilized vitronectin. This interaction is considered functionally important as several studies in cell culture clearly show that the level of uPAR expression regulates vitronectin-dependent cell adhesion and motility (21, 22, 25, 27, 40) . However, in cells with a low to moderate level of uPAR expression, the uPAR-dependent adhesion to vitronectin is also controlled by the level of receptor saturation with its cognate protease ligand uPA (21, 27) . This emphasizes the importance of the tri-molecular pro-uPA⅐uPAR⅐vitronectin complex in the regulation of this process.
The identification of the functional epitope on uPAR for vitronectin binding combined with our previous identification of the functional epitope for uPA binding (8, 11) has enabled us to assemble a low resolution model for these interactions as represented by the cartoon shown in Fig. 9 . This model allows for the formation of a tri-molecular complex, in which the small SMB module of vitronectin is positioned on the "apical side" of uPAR distal to the "basal" attachment site for the glycolipid membrane anchor. This topology is particularly compelling considering that the glycolipid-anchored uPAR should be able to bind concomitantly to both the opposing matrix-embedded vitronectin and to pro-uPA. Importantly, the identified functional epitope for the uPAR-vitronectin interaction forms a coherent surface-exposed patch on uPAR with a size comparable with the corresponding epitope identified on the SMB mod- Residues in uPAR considered important for vitronectin binding were differentially mutated to several different amino acids and tested for vitronectin binding in the presence of 10 nM pro-uPA as described in the legend to Fig. 2 . Also shown is the vitronectin binding of two purified uPAR mutants derived by homology "scanning" mutagenesis during which defined uPAR sequences were exchanged with the corresponding sequences found in CD59 as published previously (12) . uPAR N172-K175 , NTTK 175 replaced by KKDL and uPAR E183-N186 , ELEN 186 replaced by GTSL.
ule (Fig. 9 ). This observation is excellently aligned with previous biochemical studies highlighting the SMB domain of vitronectin as the primary interaction site on vitronectin for uPAR (38) . According to our model, the functional binding sites for uPA and vitronectin are completely nonoverlapping and well separated on the various structures of uPAR solved by x-ray crystallography (17) (18) (19) . Nonetheless, domain I of uPAR plays a central role in both interactions, as it provides several distinct hot spot residues for each of these two ligands. The high affinity of the uPA-uPAR interaction is achieved through the burial of large parts of the growth factor domain of uPA in a central ligand-binding cavity that is created by the assembly of all three domains of uPAR (Fig. 9) (8, (17) (18) (19) . Several hydrophobic side chains, which contribute significantly to the stability of the uPA⅐uPAR complex, are located on the "inner" side of the central four-stranded ␤-sheet in uPAR domain I that faces the ligand-binding cavity, (␤IF) (8, 11) . In contrast to this, residues in uPAR domain I, which are involved in vitronectin binding, are located on two exposed loops that connect this four-stranded ␤-sheet, i.e. Trp 32 (␤IC to ␤ID) and Arg 58 and Ile 63 (␤IE to ␤IF). Furthermore, positions characterized as being of moderate importance for the vitronectin interaction are located on proximal regions of the corresponding ␤-strands (␤IC, Arg 30 ; ␤ID, Glu 37 ), and their side chains are also excluded from the central uPA-binding cavity. Together, these comprehensive alanine-scanning mutagenesis data provide strong evidence for a direct role of uPAR domain I in the interaction with vitronectin. This conclusion is further consolidated by the finding that a monoclonal anti-uPAR antibody (R3), which inhibits adhesion to vitronectin of cells overexpressing uPAR in the absence of uPA (27, 40) , also interferes with direct vitronectin binding to uPAR in a purified system (29) . The functional epitope for this antibody (Glu 33 , Leu 61 , and Lys 62 ) is accordingly confined to the same two loops connecting the central four-stranded ␤-sheet in uPAR domain I (loops 2 and 3) that we now show to be essential for vitronectin binding.
Two additional residues located outside uPAR domain I contribute significantly to vitronectin binding (Arg  91 and Tyr  92 ) , with Arg 91 in particular representing a dominant hot spot for this interaction. Both residues are located in the flexible linker region between uPAR domains I and II, which is not well defined by the electron densities in either of the two different crystal structures solved for uPAR (17, 18) . Interestingly, this linker region has been implicated in the chemotactic effect of the receptor that is elicited either by uPA binding (41) or by proteolytic cleavage of the linker region (41, 42) and that involves activation of the FPRL1 receptor (43) . The present assignment of the vitronectin-binding site to this particular region in uPAR suggests that the engagement of uPA⅐uPAR complexes in vitronectin binding during cell adhesion would most likely preclude a concomitant ligand-induced chemotactic effect (41) . Chemotaxis is thought to be mediated by a pentapeptide Ser 88 -Arg-Ser-Arg-Tyr 92 situated in the linker region (42, 44) , which would presumably be shielded by vitronectin binding. Our data clearly show that the two last residues of this pentapeptide provide an indispensable contribution to the functional epitope on uPAR for vitronectin binding (Figs. 3, 6 , and 9). The proposed interaction between this chemotactic peptide in uPAR and the FPRL1 receptor (43) can therefore occur only under conditions where uPAR is not engaged in vitronectin binding.
By using homologue-scanning mutagenesis, Li et al. (12) have previously attempted to identify the vitronectin-bindingsite on uPAR by exchanging short sequences in the three-domain uPAR with equivalent regions found in the single domain homologue CD59. This approach identified two short stretches located in uPAR domain II (residues 172-175) and the adjacent linker region to domain III (residues 183-186) that impaired vitronectin binding when mutated but had no effect on uPA binding. These data are not easily reconciled with the present assignment of the small, well defined functional epitope on prouPA⅐uPAR complexes for immobilized vitronectin. One potential explanation for this inconsistency relates to the inherent conformational instability of the multidomain structure of uPAR, when the ligand-binding cavity is unoccupied. The presence of a large solvent-exposed hydrophobic surface on the one side of uPAR domain I facing the ligand-binding cavity (17) (18) (19) presumably confers some instability to the native, unoccupied uPAR. In accordance, we have previously shown that purified, monomeric, and recombinant uPAR WT does indeed slowly form dimers in solution when stored at 4°C (45) . In addition, the binding isotherms shown in Fig. 7B indicate the occurrence of a latency transition of the immobilized uPAR with respect to SMB binding that can be counteracted by occlusion of the uPAbinding cavity. In the present mutagenesis study, vitronectin binding was analyzed using ligand-stabilized pro-uPA⅐uPAR complexes, whereas Li et al. (12) probed the various mutants by comparing cell adhesion to vitronectin in the absence of uPA. Therefore, it is possible that some of the exchange mutations impaired the stability of the unoccupied receptor to such an extent that vitronectin binding was compromised because of indirect structural effects rather than targeting the vitronectinbinding site per se. However, in our study the effect of such unintended structural perturbations is most likely attenuated by occupancy of the hydrophobic ligand-binding cavity. This robust approach is therefore considered to provide the more reliable identification of the functional epitope on uPAR for vitronectin binding. Furthermore, although homologueswapping mutagenesis is an appealing technique for epitope mapping studies, it is less suited to a comparison between an autonomous single domain protein (CD59) and a complex multidomain protein whose functional integrity critically (Fig. 6, upper panel) or the equilibrium binding isotherms for SMB (Fig. 6, lower panel) . The R max values in RU were transformed to binding densities (B max ) in fmol/mm 2 using the approximation that 1000 RU equals 1 ng/mm 2 and the experimentally determined masses for GFD (6189 Da) and SMB (6151 Da). NB indicates no specific binding could be detected for these mutants by this method as argued in Fig. 6 Fig. 7) . Note, the data presented in Tables 2 and 3 . Defining the functional epitope in vitronectin for uPAR-prouPA. Equal levels of the indicated vitronectin derivatives were immobilized on microtiter plates and incubated with 10 nM preformed pro-uPA⅐uPAR complexes. Specific binding was quantified by subsequent incubation with a Eu 3ϩ -labeled anti-uPA clone 5 monoclonal antibody and is shown relative to that obtained with immobilized recombinant vitronectin-(1-121). Insignificant binding of 10 nM pro-uPA to vitronectin-(1-121) was detected in the absence of uPAR (Ϫ). Nonspecific binding from uncoated wells has been subtracted, but this was always less than 5% of wild-type binding. Each bar represents the mean value of 6 -10 measurements. FIGURE 9. Cartoon of the tri-molecular ATF⅐uPAR⅐SMB complex based on alanine-scanning mutagenesis. The proposed model of the complex between uPAR, ATF, and SMB is shown as a ribbon diagram. The SMB domain of vitronectin is positioned manually on the uPAR-ATF structure without any energy minimization attempts. The homologous three-finger fold domains of uPAR are highlighted by yellow (domain I), blue (domain II), and red (domain III), and the position of the glycolipid anchor, which tethers uPAR to the cell membrane, is also indicated. The ATF of uPA is shown in light blue, whereas the SMB domain of vitronectin is shown in green. ␣-Helices are colored red. The side chains identified in this study by alanine-scanning mutagenesis to be important for the interaction between uPAR⅐pro-uPA complexes and immobilized full-length vitronectin are shown as white sticks with preservation of the orientations defined in the original x-ray structures. Note that the key residue Arg 91 is not shown in this illustration as the electron densities in neither of the two solved uPAR structures (17, 18) define this residue. The Protein Data Bank coordinates used to construct this model are 2FD6 (uPAR-ATF) (18) and 1OC0 (SMB-PAI-1) (46) using the PyMOL software (DeLano Scientific).
Despite these similarities in the functional epitopes for vitronectin binding, it should be emphasized that the affinities of the two reactions differ substantially as the PAI-1-SMB interaction has a K D of 0.3 nM (48), whereas the uPAR-SMB has a K D of 1.9 M (Table 2) . Although the affinity for SMB is increased ϳ4-fold using pro-uPA⅐uPAR complexes, the measured K D of 0.4 M (Table 3 ) (48) is not sufficiently tight to account for the binding isotherms observed for the interaction between prouPA⅐uPAR complexes and immobilized vitronectin (Fig. 1) . It is therefore possible that additional regions located in uPA may contribute to the interaction between uPA⅐uPAR complexes and multimeric vitronectin. Accordingly, we and others (25) find that binding of uPA, but not its receptor-binding GFD module, supports the interaction between the corresponding uPAR complexes and immobilized vitronectin. Although the identity of a vitronectin-binding site on uPA remains to be established experimentally, it is noteworthy that a low affinity interaction of uPA with vitronectin, outside of the SMB, has been reported previously (49) . Further studies are required, however, to establish the importance of this additional contribution from uPA to the interaction between uPA⅐uPAR complexes and immobilized vitronectin.
